Health Care Supplies(IN20248.HK)

Last Updated 08:00:00
longbridge loading
Company Encyclopedia
View More
name
Health Care Supplies
IN20248.HK
News
View More

Huakang Biomedical Holdings Co. Ltd. Held Extraordinary General Meeting

Huakang Biomedical Holdings Co. Ltd. held an extraordinary general meeting on January 15, 2026, where shareholders approved a proposed change of the company name. This information was published via the Issuer Information Service of the Hong Kong Stock Exchange.

Reuters·
HK
08622
-2.38%
Reuters·
HK
08622
-2.38%

There's No Escaping Kaisa Health Group Holdings Limited's (HKG:876) Muted Revenues Despite A 27% Share Price Rise

Kaisa Health Group Holdings Limited (HKG:876) has seen a 27% share price increase in the last month, contributing to a 323% rise over the past year. Despite this, the company's price-to-sales (P/S) ratio of 2.8x remains low compared to industry peers, reflecting concerns over declining revenues, which fell 8.5% last year. The market's skepticism about future revenue growth, especially against an industry growth forecast of 43%, keeps the P/S ratio subdued. Investors are cautious, with potential risks affecting sentiment and share price stability.

Simplywall·
HK
00876
+20.34%
Simplywall·
HK
00876
+20.34%

BD transactions and policy dividends resonate, the pharmaceutical sector will have a strong rebound in 2025

The overseas expansion of innovative drugs and BD transactions have driven the explosive growth of stock prices in the pharmaceutical sector. By 2025, net purchases from southbound funds are expected to reach HKD 1.4 trillion, with the Hong Kong Stock Exchange Healthcare Index increasing by 76% this year. Structural differentiation is evident in the biopharmaceutical sector, with companies possessing First-in-Class or Best-in-Class R&D pipelines being more favored. The medical devices and supplies sector has performed well, with representative companies such as WEIGAO GROUP and MICROPORT seeing increases of 38% and 76% respectively this year

BambooWorks·
HK
01066
0.00%
HK
00853
-1.54%
BambooWorks·
HK
01066
0.00%
HK
00853
-1.54%

WEIGAO GROUP sells Weigao Purui for a final consideration of 8.5 billion RMB in exchange for over 260 million A shares of Weigao Blood Purification

WEIGAO GROUP announced the sale of 95.9784% equity in WEIGAO PURUI to Weigao Blood Purification, with a final consideration of approximately 8.511 billion RMB. Weigao Blood Purification will issue 272 million shares as consideration shares, priced at 31.29 RMB per share. After the transaction is completed, WEIGAO GROUP's shareholding in Weigao Blood Purification will increase from 23.53% to 52.10%, becoming its flagship platform for medical devices

AASTOCKS·
HK
01066
0.00%
SH
603014
-1.47%
AASTOCKS·
HK
01066
0.00%
SH
603014
-1.47%

Huachuang Securities Sticks to Their Buy Rating for Shanghai Conant Optical Co. Ltd. Class H (2276)

In a report released yesterday, from Huachuang Securities maintained a Buy rating on Shanghai Conant Optical Co. Ltd. Class H, with a price target of HK$63.63.Claim 70% Off TipRanks This Holiday SeasonUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Currently, the analyst consensus on Shanghai Conant Optical Co. Ltd. Class H is a Strong Buy with an average price target of HK$61.45.

Tip Ranks·
HK
02276
-3.45%
Tip Ranks·
HK
02276
-3.45%
Posts
View More
© 2026 Longbridge｜Disclaimer